LJI308
| CAS No. | 1627709-94-7 | Cat. No. | BCP24149 |
| Name | LJI308 | ||
| Synonyms | LJI-308; LJI 308; NVP-LJI308; NVP-LJI-308; NVP-LJI 308; | ||
| Formula | C21H18F2N2O2 | M. Wt | 368.38 |
| Description | LJI308 is a RSK inhibitor. LJI308 overcomes chemoresistance by eliminating cancer stem cells. LJI308 targets the CSC population and repress TNBC growth and dissemination. LJI308 specifically targeted transformed cells as it had little effect on the non-tumorigenic parental HMECs. Targeting RSK using specific and potent inhibitors, such as LJI308, delivers the promise of inhibiting the growth of TNBC. | ||
| Pathways | PI3K/Akt/mTOR MAPK Pathway | ||
| Targets | RSK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.